ArticleGastro hep advances2026
Rapamycin Attenuates Acute Pancreatitis-Induced Acinar Injury in Mice With Pancreatic Loss of Gα13.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background and Aims: While Gα13 transduces signals from G protein-coupled receptors to regulate inflammation, its role in pancreatitis remains poorly understood. This study aims to understand how Gα13 regulates pancreatitis-induced inflammation and acinar injury. Methods: Expression of Gα13 in mouse and human pancreas tissue was examined by immunostaining. Experimental pancreatitis was induced by administering cerulein to mice with wild-type and conditional knockout of Gα13 in the pancreas. The impact of Gα13 loss on pancreatitis was assessed by histology, immunostains, and cytokine proteome array. The Gα13-deficient mice were cotreated with the mammalian target of rapamycin (mTOR) inhibitor rapamycin during cerulein treatment to determine the effects of mTOR inhibition on pancreatitis. Results: We found reduced Gα13 expression in acute and chronic human pancreatitis samples. We show that induction of acute and chronic pancreatitis in mice with cerulein treatment reduces Gα13 expression. Moreover, we found worsening of acute and chronic pancreatitis-induced acinar injury in mice with pancreas-specific deletion of Gα13. While pancreatic deletion of Gα13 did not exacerbate acute pancreatitis-induced inflammation, we found that Gα13 loss mildly exacerbated chronic pancreatitis. Gα13 loss increased cerulein-induced mTOR signaling in the acute and chronic pancreatitis mouse models; however, the mTOR inhibitor rapamycin attenuated the effects of cerulein only in the acute pancreatitis model, whereas it exacerbated the effects of cerulein in the chronic pancreatitis model. Conclusion: This work demonstrates that Gα13 loss promotes tissue damage in acute and chronic pancreatitis, which can be attenuated by the mTOR inhibitor rapamycin in acute pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.